Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.42)
# 3,937
Out of 4,829 analysts
35
Total ratings
18.52%
Success rate
-29.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.36 | +1,287.73% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $7.94 | +277.83% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $23.83 | +38.48% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $1.34 | +497.01% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $18.35 | +172.48% | 2 | Feb 14, 2025 | |
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $36.98 | -21.58% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $8.60 | +74.42% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $10.18 | +204.52% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $32.17 | +86.51% | 2 | Jan 21, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $100.27 | +39.62% | 2 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.55 | +222.58% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.58 | +153.16% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $6.52 | +743.56% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.15 | +1,030.43% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.45 | +73.01% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.36 | +1,278.17% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.94 | +930.93% | 1 | May 14, 2024 |
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.36
Upside: +1,287.73%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $7.94
Upside: +277.83%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $23.83
Upside: +38.48%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $1.34
Upside: +497.01%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $18.35
Upside: +172.48%
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $36.98
Upside: -21.58%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $8.60
Upside: +74.42%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $10.18
Upside: +204.52%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $32.17
Upside: +86.51%
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $100.27
Upside: +39.62%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.55
Upside: +222.58%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.58
Upside: +153.16%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $6.52
Upside: +743.56%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.15
Upside: +1,030.43%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $14.45
Upside: +73.01%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.36
Upside: +1,278.17%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.94
Upside: +930.93%